Dear Sir, Please find attached copy of News Paper Publication in which Audited Financial Results for the Quarter and Year ended 31st March 2026 are published, one in English and one in ....
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Omkar Pharmachem Limited has submitted to BSE the newspaper advertisement copies (English and vernacular) carrying its audited financial results for Q4 FY26 and full year FY26. For FY26, total income from operations stood at Rs. 46.50 crore, down from Rs. 54.00 crore in FY25. Despite the revenue decline, net profit after tax jumped sharply to Rs. 12.18 crore in FY26, compared to Rs. 2.00 crore in FY25. In Q4 FY26 alone, the company reported a PAT of Rs. 1.50 crore versus a marginal loss of about Rs. 0.02 crore in Q4 FY25. The board had approved the results on 30 May 2026 after audit committee review, and other equity moved from a negative Rs. 65 lakh to a positive Rs. 26.56 crore. EPS for FY26 came in at Rs. 0.87.
Sharp profit turnaround despite lower revenue signals improved margins and a one-time recovery; positive for shareholders on earnings quality, though the drop in top-line and small absolute size mean limited immediate price catalysts. The swing in other equity from negative to positive is a notable balance-sheet improvement.